Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

2.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

3.

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group.

Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71. Epub 2007 Sep 13.

PMID:
17872493
5.

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.

Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.

Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558. Epub .

PMID:
19828470
6.

Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.

Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):464-70. doi: 10.1016/j.anai.2010.04.003.

PMID:
20568377
7.

Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia.

Antoniu SA.

Expert Opin Investig Drugs. 2009 Jun;18(6):869-71. doi: 10.1517/13543780902922678 .

PMID:
19426126
8.

Mepolizumab and eosinophil-mediated disease.

Walsh GM.

Curr Med Chem. 2009;16(36):4774-8. Review.

PMID:
19929788
9.

Sputum and blood eosinophils during corticosteroid treatment of acute exacerbations of asthma.

Baigelman W, Chodosh S, Pizzuto D, Cupples LA.

Am J Med. 1983 Dec;75(6):929-36.

PMID:
6650547
10.

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators.

N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.

11.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

12.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators.

N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777.

13.

Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization.

Di Franco A, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Taccola M, Vagaggini B, Zingoni M, Paggiaro PL.

Pulm Pharmacol Ther. 2006;19(5):353-60. Epub 2005 Nov 11.

PMID:
16289980
14.

Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.

Belda J, Margarit G, Martínez C, Bellido-Casado J, Casan P, Torrejón M, Brufal M, Rodríguez-Jerez F, Sanchis J.

Eur Respir J. 2007 Dec;30(6):1143-9. Epub 2007 Aug 9.

15.

Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.

Liu Y, Zhang S, Li DW, Jiang SJ.

PLoS One. 2013;8(3):e59872. doi: 10.1371/journal.pone.0059872. Epub 2013 Mar 27. Erratum in: PLoS One. 2013;8(6). doi: 10.1371/annotation/8da4be4b-2de1-4c51-9c40-0f49dc212579.

16.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.

Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.

PMID:
22901886
17.

Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.

Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, Hargreave FE.

Eur Respir J. 2005 Jan;25(1):41-6.

18.

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS.

Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. Epub 2002 Oct 17.

PMID:
12406833
19.

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.

J Allergy Clin Immunol. 2001 Aug;108(2):250-7.

PMID:
11496242
20.

Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients.

Giannini D, Di Franco A, Cianchetti S, Bacci E, Dente FL, Vagaggini B, Paggiaro PL.

Clin Exp Allergy. 2000 Dec;30(12):1777-84.

PMID:
11122217
Items per page

Supplemental Content

Write to the Help Desk